---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-22-031356"
form_type: "8-K"
ticker: "ELTP"
cik: "0001053369"
company_name: "ELITE PHARMACEUTICALS INC /NV/"
filed_at: "2022-11-10T23:59:59+00:00"
generated_at: "2026-06-21T22:08:03.578814+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Elite Pharmaceuticals and Lannett terminate Vigabatrin agreement; marketing rights return to Elite

## Summary
- Joint termination of License, Supply and Distribution Agreement for Vigabatrin effective Nov 9, 2022.
- All marketing rights for Vigabatrin revert to Elite Pharmaceuticals.
- Agreement was with Lannett Company, Inc.; no further details on reason or financial impact.

## SEC filing metadata
- accession: 0001493152-22-031356
- form_type: 8-K
- ticker: ELTP
- cik: 0001053369
- company_name: ELITE PHARMACEUTICALS INC /NV/
- filed_at: 2022-11-10T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1053369/000149315222031356/0001493152-22-031356-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1053369/000149315222031356/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-22-031356
- JSON: https://secwatch.observer/filing/0001493152-22-031356.json
- Plain text: https://secwatch.observer/filing/0001493152-22-031356.txt

## Key facts
- Material Agreements
  ELITE PHARMACEUTICALS INC /NV/ terminated License, Supply and Distribution Agreement with Lannett Company, Inc. (effective 2022-11-09).
  - Action: termination
  - Agreement: license
  - Counterparty: Lannett Company, Inc.
  - Effective: 2022-11-09
  source text: On November 9, 2022, Elite Pharmaceuticals Inc. (“Elite”) and Lannett Company, Inc. (“Lannett”) jointly terminated the License, Supply and Distribution Agreement for Vigabatrin effective as of November 9, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1053369/000149315222031356/0001493152-22-031356-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.